Targets › AVPR1B
6 programs from 6 companies in 19 trials: 8 Phase 3, 5 Phase 4, 3 Phase 2, 3 Phase 1; Metabolic and endocrine, Genitourinary, Gastroenterology; next expected readout Jan 2027.
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.; FUNCTION: (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, may recognize and internalize the complex formed by AVP/Arg-vasopressin, SARS-CoV-2 spike protein and secreted ACE2 through DNM2/dynamin 2-dependent endocytosis. (UniProt, P47901)
Open in Phaseline: the race on AVPR1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tiohundra | Vasopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock … | Jan 2027 |
| Hamilton Health Sciences Corporation | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Chronic Kidney Diseases | Feb 2027 |
| Assistance Publique - Hôpitaux de Paris | Desmopressin Acetate Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Hyponatremia | Dec 2027 |
| Medical University of Bialystok | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Kidney Biopsy | – |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 2 | Cushing Syndrome | Oct 2028 |
| PharmaIN | Terlipressin (PHIN-214) Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent | AVPR1A, AVPR1B, AVPR2 | Phase 1 | Cirrhosis, Liver | – |
Sepsis (2) Septic Shock (2) Hyponatremia (1) Kidney Biopsy (1) Cushing Syndrome (1) Chronic Kidney Diseases (1) Cirrhosis, Liver (1) Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial (1) Vasoplegic Syndrome of Cardiac Surgery (1) Retained Products of Conception (1) Shock (1) Scheduled Cardiac Surgery With Extracorporeal Circulation (1)
small molecule (6)
Assistance Publique - Hôpitaux de Paris (1) Medical University of Bialystok (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Hamilton Health Sciences Corporation (1) PharmaIN (1) Tiohundra (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.